Metastatic Breast Cancer

Having social media platforms to share breast cancer experiences changes the narrative for others who may empathize, a survivor and advocate said.

Enhertu lengthened the time to progression in patients with HR-positive, HER2-low or -ultralow metastatic breast cancer.

The Food and Drug Administration granted a breakthrough therapy designation to inavolisib plus Ibrance and fulvestrant for HR-positive, HER2-negative locally advanced or metastatic breast cancer.

When I received news of a fellow blogger’s demise, I was heartbroken.

After seeing how palliative care helped me through cancer, I now advocate for these services to other patients.

The FDA has approved Hercessi for the adjuvant treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Prompted by a celebrity diagnosis of breast cancer, I looked at tools that could help my own kids.

My metastatic breast cancer has caused metastases to my brain, so it's important I advocate for my brain when symptoms arise.

Recurrence is common enough that all of us need to act on potential symptoms.

During the CURE Educated Patient® Breast Cancer Summit, an expert discussed her professional and personal experience with side effect management in metastatic breast cancer.

Bluebonnets are a tenacious flower, which have taught me to be tenacious through breast cancer.

When people tell me I have metastatic cancer, I don't let their doom and gloom stop me — I'm going to bloom like a flower.

A time to reflect on changes we can make while we still have time, despite having cancer.

Researchers on a phase 1b/2 trial dosed their first patient with samuraciclib and ARV-471, a novel treatment regimen for patients with a breast cancer subset.

Michelle Anderson-Benjamin, who received a diagnosis of metastatic breast cancer in 2022, works as a death doula to provide end-of-life support to patients and their families.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

I felt like I had to come back to life after hearing the word “metastatic.”

The Food and Drug Administration granted a Fast Track designation to the novel drug, ARV-471 for patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer.

Cancer is a dark place, but we can bring light to it.

Wait for the other shoe to drop, or grab each day for all it’s worth?

Soon after experiencing headaches and other symptoms, I spoke up to my oncologist — and I’m glad I did.

The introduction of Tukysa to Kadcyla emtansine significantly improved progression-free survival versus placebo plus Kadcyla in patients with previously treated HER2-positive metastatic breast cancer.

Patients with HR-positive HER2-negative advanced breast cancer, including elderly patients, derived a progression-free and overall survival benefit with Kisqali plus endocrine therapy compared with placebo plus endocrine therapy.

As Shannen Doherty revealed her cancer diagnoses and upcoming podcast and a woman with breast cancer completed her bucket list, here is what’s happening in the oncology space this week.

Dato-DXd lengthened the average time it took patients with HR-positive, HER2-low or -negative metastatic breast cancer to experience disease progression, study results showed.